SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) Chairman Jurgi Camblong sold 20,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $7.23, for a total transaction of $144,600.00. Following the completion of the sale, the chairman owned 3,452,822 shares of the company’s stock, valued at $24,963,903.06. This trade represents a 0.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jurgi Camblong also recently made the following trade(s):
- On Monday, August 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.61, for a total transaction of $64,685.00.
- On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total transaction of $138,400.00.
- On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.63, for a total transaction of $132,600.00.
- On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.29, for a total value of $153,356.49.
- On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total value of $47,770.00.
- On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total value of $93,376.80.
- On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total value of $118,051.50.
- On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $7,826.10.
- On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total value of $290,400.20.
- On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total transaction of $44,540.00.
SOPHiA GENETICS Price Performance
Shares of SOPH stock opened at $7.57 on Thursday. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The company has a market capitalization of $635.05 million, a P/E ratio of -6.58 and a beta of 0.96. The company’s 50-day simple moving average is $5.79 and its two-hundred day simple moving average is $5.19. SOPHiA GENETICS SA has a one year low of $2.99 and a one year high of $7.88.
Institutional Investors Weigh In On SOPHiA GENETICS
Hedge funds and other institutional investors have recently bought and sold shares of the company. Sei Investments Co. purchased a new stake in shares of SOPHiA GENETICS during the 1st quarter valued at $1,772,000. 1492 Capital Management LLC purchased a new position in SOPHiA GENETICS during the 4th quarter worth $973,000. Royce & Associates LP purchased a new position in SOPHiA GENETICS during the 4th quarter worth $2,009,000. Hodges Capital Management Inc. acquired a new position in SOPHiA GENETICS during the 1st quarter valued at about $2,157,000. Finally, Royal Bank of Canada increased its position in SOPHiA GENETICS by 3,130.2% during the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after buying an additional 18,781 shares in the last quarter. Hedge funds and other institutional investors own 31.59% of the company’s stock.
Analysts Set New Price Targets
Several brokerages have issued reports on SOPH. HC Wainwright raised their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research boosted their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, SOPHiA GENETICS presently has an average rating of “Hold” and a consensus target price of $10.00.
View Our Latest Research Report on SOPHiA GENETICS
About SOPHiA GENETICS
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Featured Stories
- Five stocks we like better than SOPHiA GENETICS
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
